Skip Navigation


The global source of news, directories, proprietary market research, and analysis for clinical trials professionals and patients.

Bookmark | Print | E-Mail

Receive E-mails About New Clinical Trials!

Sign up for our FREE service and we'll send you automatic e-mail notifications as soon as a clinical trial is posted in the medical category you're interested in.






Home » Drug Information » FDA-Approved Drugs » 1998
Medical Areas: Cardiology/Vascular Diseases | Endocrinology

View By: Year Company Therapeutic Areas Drug Names 

Drug Information

The following information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Drug Name: Diovan HCT (valsartan)

Company: Novartis
Approval Status: Approved March 1998
Treatment Area: second-line treatment of hypertension

General Information

Diovan HCT has been approved for second-line treatment of hypertension. Diovan HCT is a combination of an angiotensin II receptor blocker (ARB)--a first line treatment that lowers blood pressure with an overall incidence of side effects comparable to placebo--and a diuretic, which is commonly used with other therapies to provide additional blood pressure lowering.


Jobson Medical Information

Copyright © 1995-2009 Jobson Medical Information LLC.


Designed by Piehead Productions LLC.